Tampere, Finland

Maria Malm

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Icon Genetics Gmbh. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Maria Malm: Innovator in Immunogenic Composition and Vaccine Development

Introduction

Maria Malm is a prominent inventor based in Tampere, Finland. She has made significant contributions to the field of immunology, particularly in the development of vaccines. Her innovative work focuses on generating immune responses to norovirus, a virus that poses a significant health risk worldwide.

Latest Patents

Maria Malm holds a patent for an immunogenic composition and vaccine designed to generate an immune response to norovirus. This composition includes at least one Norovirus antigen and at least one adjuvant, specifically the B subunit of an AB toxin, such as cholera toxin subunit B (CTB) or the B subunit of heat-labile exotoxin LT (LTB). This patent represents a crucial advancement in vaccine technology and has the potential to improve public health outcomes.

Career Highlights

Maria is currently employed at Icon Genetics GmbH, where she continues her research and development efforts. Her work at this company has allowed her to collaborate with other experts in the field and contribute to groundbreaking innovations in vaccine development.

Collaborations

Maria has worked alongside notable colleagues, including Vesna Blazevic and Frank Thieme. These collaborations have enriched her research and expanded the impact of her inventions.

Conclusion

Maria Malm's contributions to immunogenic composition and vaccine development highlight her role as a leading inventor in the field. Her innovative work continues to pave the way for advancements in public health and vaccine technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…